All In Biotech

Drug Trial Radar · NCT04626947

Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

Last checked: Nov 20, 2026Latest source record: Jun 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

19

Actual

Start

Oct 14, 2021

Primary completion

Apr 24, 2024

Study completion May 31, 2024

Sponsor

Lead sponsor
David Binion, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Merck Sharp & Dohme LLC
First posted
Nov 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will compare the effectiveness of Bezlotoxumab in individuals with active C. diff ( Clostridium difficile) infection who are diagnosed with Inflammatory Bowel Disease.

Conditions

  • Inflammatory Bowel Diseases
  • Ulcerative Colitis
  • Crohn Disease
  • C. Diff. Infections

Interventions

  • BezlotoxumabBiological

    Bezlotoxumab infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Recurrent C. Diff Infection at 90 DaysTime frame: 90 days
  2. Number of Participants With Recurrent C. Diff Infection at 12 MonthsTime frame: 12 months
  3. Number of Participants With Recurrent C. Diff Infection at 24 MonthsTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.